UPyTher develops controlled-release hydrogel-drug formulations specifically for intraperitoneal administration, enhancing local drug exposure for the treatment of peritoneal carcinomatosis. This technology addresses the inadequate drug delivery and short exposure duration associated with traditional intravenous therapies, improving therapeutic efficacy and patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional intravenous drug delivery methods for peritoneal carcinomatosis result in inadequate drug exposure and short duration of action within the peritoneal cavity. This limits the effectiveness of existing drugs in treating peritoneal metastases, leading to poor patient outcomes and reduced quality of life.
Solution
UPyTher develops hydrogel-based drug formulations designed for direct intraperitoneal administration, creating a sustained-release drug depot within the peritoneal cavity. The liquid formulation is easily injected and evenly distributes throughout the abdomen, converting into a soft, elastic gel that prolongs drug exposure to tumor sites. This locoregional treatment approach aims to improve the therapeutic effects of existing drugs by enhancing drug delivery and maintaining therapeutic concentrations for extended periods, ultimately improving patient outcomes in peritoneal carcinomatosis.
Target Audience
The primary target audience includes oncologists and hospitals specializing in the treatment of peritoneal carcinomatosis, as well as pharmaceutical companies seeking to improve the delivery and efficacy of their oncology drugs.
Features
- Injectable liquid formulation that distributes evenly within the peritoneal cavity
- In-situ gel formation for sustained drug release
- Supramolecular UPy-chemistry for controlled drug release kinetics
- Enhanced drug exposure to peritoneal tumor sites
- Compatibility with existing clinical practices for intraperitoneal administration